Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Impact · against what's priced in

The current price action for AbbVie, Eli Lilly, and Gilead reflects a broader sector rotation rather than company-specific catalysts. Since these stocks are trading at record highs, the market has already fully baked in current growth trajectories, leaving the stocks sensitive to execution risks rather than new upside.

LLY+0.00: Already priced in
The price assumes: Revenue guidance of $85–87 billion for 2026

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Track these names every morning.

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Medical Developments International Limited (MDDVF) Discusses Leadership Transition, Business Performance, and Strategic Growth Initiatives Transcript

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Track these names every morning.

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Medical Developments International Limited (MDDVF) Discusses Leadership Transition, Business Performance, and Strategic Growth Initiatives Transcript